Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Abstract

T cells directed against mutant neo-epitopes drive cancer immunity. However, spontaneous immune recognition of mutations is inefficient. We recently introduced the concept of individualized mutanome vaccines and implemented an RNA-based poly-neo-epitope approach to mobilize immunity against a spectrum of cancer mutations1,2. Here we report the first-in-human application of this concept in melanoma. We set up a process comprising comprehensive identification of individual mutations, computational prediction of neo-epitopes, and design and manufacturing of a vaccine unique for each patient. All patients developed T cell responses against multiple vaccine neo-epitopes at up to high single-digit percentages. Vaccine-induced T cell infiltration and neo-epitope-specific killing of autologous tumour cells were shown in post-vaccination resected metastases from two patients. The cumulative rate of metastatic events was highly significantly reduced after the start of vaccination, resulting in a sustained progression-free survival. Two of the five patients with metastatic disease experienced vaccine-related objective responses. One of these patients had a late relapse owing to outgrowth of β2-microglobulin-deficient melanoma cells as an acquired resistance mechanism. A third patient developed a complete response to vaccination in combination with PD-1 blockade therapy. Our study demonstrates that individual mutations can be exploited, thereby opening a path to personalized immunotherapy for patients with cancer.

Article Site: https://www.nature.com/articles/nature23003

Original Document: https://www.nature.com/articles/nature23003.pdf

Related Post

Biocon’s Target Factory
views 26
South Korea's 8-year effort to create an integrated platform for novel target and lead development provides an academic drug discovery model for...
Stocking oncology’s medicine cabinet
views 2201
Stocking oncology's medicine cabinet Paula A. Kiberstis, John Travis Science  17 Mar 2017: Vol. 355, Issue 6...
Global Oncology Trends 2018 – Innovation, Ex...
views 25
About the Report Cancer treatments have been advancing at an accelerated pace in recent years, offering notable improvements in clinical benefit to p...
Trends in the global immuno-oncology landscape
views 29
Jun Tang, Laura Pearce, Jill O'Donnell-Tormey & Vanessa M. Hubbard-Lucey Nature Reviews Drug Discovery volume 17, pages 783–784 (2018) The app...

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

©2010-2019 Medicinal Bioconvergence Research Center. All rights reserved.

Log in with your credentials

Forgot your details?

Skip to toolbar